Brief: Ascentage Pharma's Mdm2-P53 Inhibitor APG-115 (Alrizomadlin) Granted An Orphan Drug Designation By The FDA For The Treatment Of Stage Iib-Iv Melanoma, Marking The Twelfth Obtained By The Company
21/07/2021 11:39
July 21 (Reuters) - Ascentage Pharma Group International
6855.HK :
* ASCENTAGE PHARMA'S MDM2-P53 INHIBITOR APG-115
(ALRIZOMADLIN)
GRANTED AN ORPHAN DRUG DESIGNATION BY THE FDA FOR THE TREATMENT
OF STAGE IIB-IV MELANOMA, MARKING THE TWELFTH OBTAINED BY THE
COMPANY
Source text for Eikon: ID:nPn28V52ma
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up